iiinova — where your digital self keeps evolving

Reposted by Optivivax

University of Oxford Department of Paediatrics @paediatrics.ox.ac.uk · 01/10/2026

Malaria is a major global health problem with over 600,000 deaths worldwide in 2024. Our Draper Lab Group is looking for volunteers to help test its blood-stage vaccine. If you are aged 18 to 45 years old, then you may be eligible to take part. Find out more and sign up f.mtr.cool/x0k3e853kx

011

Optivivax @optivivax.bsky.social · 15/09/2026

Thank you to all researchers, advisors, work package leads, and partners who contributed to this year's OptiViVax Annual Meeting in Paris. Two days of productive discussions, insights, and collaboration as we work towards the next generation of malaria vaccines.

100

Optivivax @optivivax.bsky.social · 20/08/2026

🦟Today's #WorldMosquitoDay In 1897, Sir Ronald Ross discovered that Anopheles mosquitoes transmit malaria, changing the course of infectious disease research. Plasmodium vivax remains a major but often overlooked challenge. At OptiViVax we're advancing the next generation of vaccines to tackle it.

110

Optivivax @optivivax.bsky.social · 06/08/2026

Great to see this article featuring Prof. Simon Draper and Prof. Angela Minassian, alongside the wider team, highlighting efforts to develop next-generation malaria vaccines. Read the article here 👉 www.telegraph.co.uk/global-healt...

011

Optivivax @optivivax.bsky.social · 26/06/2026

We’re pleased to share another preprint, now on medRxiv: A Plasmodium vivax controlled human infection and transmission model to evaluate interventions across the life cycle. A collaboration between Radboudumc and the Draper Lab Group, as part of the OptiViVax consortium.

medrxiv.org

A Plasmodium vivax controlled human infection and transmission model to evaluate interventions across the life cycle

Background Plasmodium vivax is an underappreciated cause of malaria disease burden. No reproducible and standardized full life-cycle controlled human malaria infection (CHMI) model to accelerate devel...

021

Optivivax @optivivax.bsky.social · 25/06/2026

We’re pleased to share our latest preprint on medRxiv: a Controlled Human Malaria Infection model for relapsing Plasmodium vivax. This collaborative study from Oxford, Radboudumc and the OptiViVax consortium reports the safety and feasibility of a novel relapsing P. vivax CHMI model.

optivivax.site.ox.ac.uk

New pre-print!

121

Optivivax @optivivax.bsky.social · 28/05/2026

Konstantinos Kousis presented the latest developments in infection biology research. The talk highlighted current approaches and discoveries in the field, followed by engaging discussions with researchers who attended the seminar. #InfectionBiology #ResearchSeminar #LSHTM #BiomedicalResearch 🧪

optivivax.site.ox.ac.uk

Research Fellow Konstantinos Kousis Presents Latest Work in Infection Biology

100

Optivivax @optivivax.bsky.social · 23/01/2026

We’re hiring! Our Draper Lab Group at the University of Oxford is looking for a highly organised and proactive Project Manager to support cutting-edge malaria vaccine development. Apply by 12.00 6th February 2026: tinyurl.com/4ssx8zfa

tinyurl.com

Job Details

000

Optivivax @optivivax.bsky.social · 21/01/2026

We’re hiring! Our Draper Lab Group at the University of Oxford is looking for a highly organised and proactive professional to join a world-leading child health research environment supporting Professor Angela Minassian and the Clinical Trials team. Apply by 18 February 2026: bit.ly/3LVHLg6

bit.ly

Job Details

020